Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: A cross-sectional study

Clinical Endocrinology

Volumn 69, Issue 6, 2008, Pages 885-893

  Retnakaran, Ravi ^b,c   Youn, Byung Soo ^d   Liu, Ying ^a   Hanley, Anthony J G ^b,c   Lee, Nam Seok ^d   Park, Ji Woo ^d   Song, Eun Sun ^d   Vu, Vivian ^a   Kim, Wi ^a   Tungtrongchitr, Rungsunn ^e   Havel, Peter J ^f   Swarbrick, Michael M ^f   Shaw, Collin ^g   Sweeney, Gary ^a  

^a YORK UNIVERSITY   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Korea University   (South Korea)

^e MAHIDOL UNIVERSITY   (Thailand)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g ALPCO Diagnostics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; METFORMIN; RECOMBINANT PROTEIN; RESISTIN; SULFONYLUREA DERIVATIVE; VISFATIN;

ADIPOCYTE; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTHROPOMETRIC PARAMETERS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN SECRETION; RAT;

3T3-L1 CELLS; ADIPOCYTES; ADIPONECTIN; ANIMALS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MICE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RATS; REGRESSION ANALYSIS; RESISTIN;

EID: 55949117816     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03264.x     Document Type: Article

References (49)

1. Revollo, J.R., Grimm, A.A. Imai, S. (2007) The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Current Opinions in Gastroenterology, 23, 164 170.
2. Revollo, J.R., Korner, A., Mills, K.F., Satoh, A., Wang, T., Garten, A., Dasgupta, B., Sasaki, Y., Wolberger, C., Townsend, R.R., Milbrandt, J., Kiess, W. Imai, S. (2007) Nampt/PBEF/Visfatin regulates insulin secretion in β cells as a systemic NAD biosynthetic enzyme. Cell Metabolism, 6, 363 375.
3. Lopez-Bermejo, A., Chico-Julia, B., Fernandez-Balsells, M., Recasens, M., Esteve, E., Casamitjana, R. Ricart, W., Fernández-Real, J.M. (2006) Serum visfatin increases with progressive β-cell deterioration. Diabetes, 55, 2871 2875.
4. Hug, C. Lodish, H.F. (2005) Medicine. Visfatin: a new adipokine. Science, 307, 366 367.
5. Sethi, J.K. (2007) Is PBEF/visfatin/Nampt an authentic adipokine relevant to the metabolic syndrome? Current Hypertension Report, 9, 33 38.
6. Chen, M.P., Chung, F.M., Chang, D.M., Tsai, J.C., Huang, H.F., Shin, S.J. Lee, Y.J. (2006) Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism, 91, 295 299.
7. Dogru, T., Sonmez, A., Tasci, I., Bozoglu, E., Yilmaz, M.I., Genc, H., Erdem, G., Gok, M., Bingol, N., Kilic, S. Ozgurtas, T., Bingol, S. (2007) Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Research and Clinical Practice, 76, 24 29.
8. Hammarstedt, A., Pihlajamaki, J., Rotter Sopasakis, V., Gogg, S., Jansson, P.A., Laakso, M. Smith, U. (2006) Visfatin is an adipokine, but it is not regulated by thiazolidinediones. Journal of Clinical Endocrinology and Metabolism, 91, 1181 1184.
9. Sandeep, S., Velmurugan, K., Deepa, R. Mohan, V. (2007) Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism, 56, 565 570.
10. Takebayashi, K., Suetsugu, M., Wakabayashi, S., Aso, Y. Inukai, T. (2007) Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism, 56, 451 458.
11. Ingelsson, E., Larson, M.G., Fox, C.S., Yin, X., Wang, T.J., Lipinska, I. Pou, K.M., Hoffmann, U., Benjamin, E.J., Keaney, J.F. Vasan, R.S 2007) Clinical correlates of circulating visfatin levels in a community-based sample. Diabetes Care, 30, 1278 1280.
12. Varma, V., Yao-Borengasser, A., Rasouli, N., Bodles, A.M., Phanavanh, B., Lee, M.J. Starks, T., Kern, L.M., Spencer, H.J., McGehee, R.E., Fried, S.K. Kern, P.A. (2007) Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. Journal of Clinical Endocrinology and Metabolism, 92, 666 672.
13. Berndt, J., Kloting, N., Kralisch, S., Kovacs, P., Fasshauer, M., Schon, M.R., Stumvoll, M. Bluher, M. (2005) Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes, 54, 2911 2916.
14. Pagano, C., Pilon, C., Olivieri, M., Mason, P., Fabris, R., Serra, R., Milan, G., Rossato, M., Federspil, G. Vettor, R. (2006) Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. Journal of Clinical Endocrinology and Metabolism, 91, 3165 3170.
15. Garcia-Fuentes, E., Garcia-Almeida, J.M., Garcia-Arnes, J., Garcia-Serrano, S., Rivas-Marin, J., Gallego-Perales, J.L. Rojo-Martínez, G., Garrido-Sánchez, L., Bermudez-Silva, F.J., Rodríguez de Fonseca, F. Soriguer, F. (2007) Plasma visfatin concentrations in severely obese subjects are increased after intestinal bypass. Obesity (Silver Spring), 15, 2391 2395.
16. Oki, K., Yamane, K., Kamei, N., Nojima, H. Kohno, N. (2007) Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clinical Endocrinology, 67, 796 800.
17. Filippatos, T.D., Derdemezis, C.S., Gazi, I.F., Lagos, K., Kiortsis, D.N., Tselepis, A.D. Elisaf, M.S. (2008) Increased plasma visfatin levels in subjects with the metabolic syndrome. European Journal of Clinical Investigations, 38, 71 72.
18. Seo, J.A., Jang, E.S., Kim, B.G., Ryu, O.H., Kim, H.Y., Lee, K.W., Kim, S.G., Choi, K.M., Baik, S.H., Choi, D.S. Kim, N.H 2008) Plasma visfatin levels are positively associated with circulating interleukin-6 in apparently healthy Korean women. Diabetes Research and Clinical Practice, 79 108 111.
19. Teoh, H., Lovren, F. Verma, S. (2007) Vascular dysfunction: a Janus face of visfatin in diabetes? Metabolism, 56, 459 461.
20. Axelsson, J., Witasp, A., Carrero, J.J., Qureshi, A.R., Suliman, M.E., Heimburger, O., Bárány, P., Lindholm, B., Alvestrand, A., Schalling, M., Nordfors, L. Stenvinkel, P. (2007) Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. American Journal of Kidney Disease, 49, 237 244.
21. Tilg, H. Moschen, A.R. (2008) Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clinical Science, 114, 275 288.
22. Liu, Y., Retnakaran, R., Hanley, A., Tungtrongchitr, R., Shaw, C. Sweeney, G. (2007) Total and high molecular weight but not trimeric or hexameric forms of adiponectin correlate with markers of the metabolic syndrome and liver injury in Thai subjects. Journal of Clinical Endocrinology and Metabolism, 92, 4313 4318.
23. Sweeney, G., Somwar, R., Ramlal, T., Volchuk, A., Ueyama, A. Klip, A. (1999) An inhibitor of p38 mitogen-activated protein kinase prevents insulin-stimulated glucose transport but not glucose transporter translocation in 3T3-L1 adipocytes and L6 myotubes. Journal of Biological Chemistry, 274, 10071 10078.
24. Sen, A., Lea-Currie, Y.R., Sujkowska, D., Franklin, D.M., Wilkison, W.O., Halvorsen, Y.D. Gimble, J.M. (2001) Adipogenic potential of human adipose derived stromal cells from multiple donors is heterogeneous. Journal of Cell Biochemistry, 81, 312 319
25. Vu, V., Kim, W., Fang, X., Liu, Y., Xu, A. Sweeney, G. (2007) Coculture with primary visceral rat adipocytes from control but not streptozotocin-induced diabetic animals increases glucose uptake in rat skeletal muscle cells: role of adiponectin. Endocrinology, 148, 4411 4419.
26. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F. Turner, R.C. (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologica, 28, 412 419.
27. Maclaren, R., Cui, W. Cianflone, K. (2007) Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes. Diabetes, Obesity and Metabolism, 9, 490 497.
28. Korner, A., Garten, A., Bluher, M., Tauscher, R., Kratzsch, J. Kiess, W. (2007) Molecular characteristics of serum visfatin and differential detection by immunoassays. Journal of Clinical Endocrinology and Metabolism, 92, 4783 4791.
29. Haider, D.G., Schaller, G., Kapiotis, S., Maier, C., Luger, A. Wolzt, M. (2006) The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologica, 49, 1909 1914.
30. Filippatos, T.D., Derdemezis, C.S., Kiortsis, D.N., Tselepis, A.D. Elisaf, M.S. (2007) Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. Journal of Endocrinological Investigations, 30, 323 326.
31. Pilz, S., Mangge, H., Obermayer-Pietsch, B. Marz, W. (2007) Visfatin/pre-B-cell colony-enhancing factor: a protein with various suggested functions. Journal of Endocrinological Investigations, 30, 138 144.
32. Wang, P., van Greevenbroek, M.M., Bouwman, F.G., Brouwers, M.C, Van der Kallen, C.J., Smit, E., Keijer, J. Mariman, E. (2007) The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile. Pflugers Archiv, 454, 971 976.
33. Adya, R., Tan, B.K., Chen, J. Randeva, H.S. (2008) Nuclear Factor κB Induction by Visfatin in Human Vascular Endothelial Cells: Role in MMP-2/9 Production and Activation. Diabetes Care, 31, 758 760.
34. McTernan, P.G., Kusminski, C.M. Kumar, S. (2006) Resistin. Current Opinions in Lipidology, 17, 170 175.
35. Pang, S.S. Le, Y.Y. (2006) Role of resistin in inflammation and inflammation-related diseases. Cell Molecular Immunology, 3, 29 34.
36. Trayhurn, P. Wood, I.S. (2004) Adipokines: inflammation and the pleiotropic role of white adipose tissue. British Journal of Nutrition, 92, 347 355.
37. Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L. Ferrante, A.W. Jr. (2003) Obesity is associated with macrophage accumulation in adipose tissue. Journal of Clinical Investigations, 112, 1796 1808.
38. Curat, C.A., Wegner, V., Sengenes, C., Miranville, A., Tonus, C., Busse, R. Bouloumié, A. (2006) Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologica, 49, 744 747.
39. Jia, S.H., Li, Y., Parodo, J., Kapus, A., Fan, L., Rotstein, O.D. Marshall, J.C. (2004) Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. Journal of Clinical Investigations, 113, 1318 1327.
40. Dahl, T.B., Yndestad, A., Skjelland, M., Oie, E., Dahl, A., Michelsen, A., Damas, J.K., Tunheim, S.H., Ueland, T., Smith, C., Bendz, B., Tonstad, S., Gullestad, L., Froland, S.S., Krohg-Sorensen, K., Russell, D., Aukrust, P. Halvorsen, B. (2007) Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation, 115, 972 980.
41. Zhang, Y.Y., Gottardo, L., Thompson, R., Powers, C., Nolan, D., Duffy, J., Marescotti, M.C., Avogaro, A. Doria, A 2006) A visfatin promoter polymorphism is associated with low-grade inflammation and type 2 diabetes. Obesity (Silver Spring), 14, 2119 2126.
42. Moschen, A.R., Kaser, A., Enrich, B., Mosheimer, B., Theurl, M., Niederegger, H. Tilg, H. (2007) Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. Journal of Immunology, 178, 1748 1758.
43. Li, L., Yang, G., Li, Q., Tang, Y., Yang, M., Yang, H. Li, K. (2006) Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Experimental and Clinical Endocrinology and Diabetes, 114, 544 548.
44. Hada, Y., Yamauchi, T., Waki, H., Tsuchida, A., Hara, K., Yago, H., Miyazaki, O., Ebinuma, H. Kadowaki, T 2007) Selective purification and characterization of adiponectin multimer species from human plasma. Biochemical and Biophysical Research Communications, 356, 487 493.
45. Fang, X. Sweeney, G. (2006) Mechanisms regulating energy metabolism by adiponectin in obesity and diabetes. Biochemistry Society of Transactions, 34, 798 801.
46. Kadowaki, T., Yamauchi, T., Kubota, N., Hara, K., Ueki, K. Tobe, K. (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. Journal of Clinical Investigations, 116, 1784 1792.
47. Pajvani, U.B., Hawkins, M., Combs, T.P., Rajala, M.W., Doebber, T., Berger, J.P., Wagner, J.A., Wu, M., Knopps, A., Xiang, A.H., Utzschneider, K.M., Kahn, S.E., Olefsky, J.M., Buchanan, T.A. Scherer, P.E. (2004) Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. Journal of Biological Chemistry, 279, 12152 12162.
48. Kobayashi, H., Ouchi, N., Kihara, S., Walsh, K., Kumada, M., Abe, Y., Funahashi, T. Matsuzawa, Y. (2004) Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circulation Research, 94, e27 31.
49. Neumeier, M., Weigert, J., Schaffler, A., Wehrwein, G., Muller-Ladner, U., Scholmerich, J., Wrede, C. Buechler, C. (2006) Different effects of adiponectin isoforms in human monocytic cells. Journal of Leukocyte Biology, 79, 803 808.